Wasyl Feniuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wasyl Feniuk has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
P.P.A. Humphrey
Glaxo Institute of Applied Pharmacology, Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QJ
3 shared publicationsM.J. Perren
2 shared publicationsP P Humphrey
2 shared publicationsA D Watts
1 shared publicationA.W. Oxford
1 shared publicationE Jarvie
1 shared publication
Latest Publications
- Open Access
- 1 March 2001
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (5) , 1102-1110
Ligand internalization and recycling by human recombinant somatostatin type 4 (h sst4) receptors expressed in CHO‐K1 cells
There is controversy as to whether somatostatin sst4 receptors internalize. In this study, CHO‐K1 cells expressing human sst4 receptor (CHOsst4 cells) cells internalized [125I]‐[11Tyr]‐SRIF in a time‐dependent manner, reaching a steady state at 60 min (1.4±0.1×104 molecules internalized per cell). Internalization was blocked by hypertonic sucrose (0.5 M), ATP depletion or by decreasing the temperature to 4°C. Internalization of [125I]‐[11Tyr]‐SRIF was also inhibited (pIC50 values) by increasing concentrations of SRIF (7.74), L‐362855 (6.27) and NNC‐296100 (6.50) with pIC50 values approximately 10 fold lower than those obtained for inhibition of [125I]‐[11Tyr]‐SRIF binding to membrane homogenates. Internalized ligand recycled rapidly to the extracellular media (t1/2 3.9±0.7 min) with only 6.8±0.6% of internalized radioactivity remaining in the cell after 45 min. Confocal microscopy of permeabilized, HA‐epitope tagged CHOsst4 cells labelled with a Cy‐3 conjugated antibody revealed little internal immunostaining after SRIF (1 μM) treatment, consistent with the small proportion of receptors (3.5%) estimated to be internalized by radioimmunoassay. In summary, CHOsst4 cells internalized [125I]‐[11Tyr]‐SRIF in a clathrin‐ and ATP‐dependent manner with subsequent rapid recycling to the extracellular medium. Rapid receptor recycling and the consequent low proportion of receptors internalized at any one time may explain the inability to visualize internalized receptors by confocal microscopy. It seems unlikely therefore that the marked receptor desensitization observed in CHOsst4 cells following SRIF treatment can be accounted for by a decrease in cell surface receptor expression. British Journal of Pharmacology (2001) 132, 1102–1110; doi:10.1038/sj.bjp.0703896
- 1 March 2001
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (5) , 1102-1110
Open AccessLigand internalization and recycling by human recombinant somatostatin type 4 (h sst4) receptors expressed in CHO‐K1 cells
There is controversy as to whether somatostatin sst4 receptors internalize. In this study, CHO‐K1 cells expressing human sst4 receptor (CHOsst4 cells) cells internalized [125I]‐[11Tyr]‐SRIF in a time‐dependent manner, reaching a steady state at 60 min (1.4±0.1×104 molecules internalized per cell). Internalization was blocked by hypertonic sucrose (0.5 M), ATP depletion or by decreasing the temperature to 4°C. Internalization of [125I]‐[11Tyr]‐SRIF was also inhibited (pIC50 values) by increasing concentrations of SRIF (7.74), L‐362855 (6.27) and NNC‐296100 (6.50) with pIC50 values approximately 10 fold lower than those obtained for inhibition of [125I]‐[11Tyr]‐SRIF binding to membrane homogenates. Internalized ligand recycled rapidly to the extracellular media (t1/2 3.9±0.7 min) with only 6.8±0.6% of internalized radioactivity remaining in the cell after 45 min. Confocal microscopy of permeabilized, HA‐epitope tagged CHOsst4 cells labelled with a Cy‐3 conjugated antibody revealed little internal immunostaining after SRIF (1 μM) treatment, consistent with the small proportion of receptors (3.5%) estimated to be internalized by radioimmunoassay. In summary, CHOsst4 cells internalized [125I]‐[11Tyr]‐SRIF in a clathrin‐ and ATP‐dependent manner with subsequent rapid recycling to the extracellular medium. Rapid receptor recycling and the consequent low proportion of receptors internalized at any one time may explain the inability to visualize internalized receptors by confocal microscopy. It seems unlikely therefore that the marked receptor desensitization observed in CHOsst4 cells following SRIF treatment can be accounted for by a decrease in cell surface receptor expression. British Journal of Pharmacology (2001) 132, 1102–1110; doi:10.1038/sj.bjp.0703896
- 1 July 2000
- Published by Elsevier in Neuropharmacology
- Vol. 39 (8) , 1443-1450
Selective somatostatin sst2 receptor blockade with the novel cyclic octapeptide, CYN-154806
- 1 July 2000
- Published by Elsevier in Neuropharmacology
- Vol. 39 (8) , 1443-1450
Selective somatostatin sst2 receptor blockade with the novel cyclic octapeptide, CYN-154806
- 1 August 1995
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 23 (3) , 459S
Calcium signalling in human colonic epithelial cells via tyrosine kinase and G-protein linked receptors
- 1 August 1995
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 23 (3) , 459S
Calcium signalling in human colonic epithelial cells via tyrosine kinase and G-protein linked receptors
- 1 November 1993
- Published by Wiley in British Journal of Pharmacology
- Vol. 110 (3) , 1156-1164
Characterization of somatostatin receptors in guinea‐pig isolated ileum, vas deferens and right atrium
1. Somatostatin14 (SS14) inhibits neurogenically mediated contractile responses in guinea-pig ileum and vas deferens and exerts a direct negative inotropic action in guinea-pig spontaneously beating right atrium. In this study, the receptors mediating these inhibitory effects have been characterized by comparing the potencies of several cyclic somatostatin analogues. 2. In the guinea-pig ileum, SS14, somatostatin28 (SS28), somatostatin25 (SS25) and several smaller cyclic somatostatin analogues including octreotide, angiopeptin and CGP 23996, inhibited neurogenically mediated contractile responses, each being of similar potency. 3. In contrast, in the guinea-pig vas deferens and right atrium, SS28 was about 30 times more potent than SS14. However, although angiopeptin was nearly as potent as SS14 as an agonist in the vas deferens, in guinea-pig atrium angiopeptin had low intrinsic activity and antagonized the negative inotropic action of both SS14 and SS28 (pKB values of 7.4 and 7.2, respectively). CGP 23996 was 2-7 times weaker than SS14 in guinea-pig vas deferens and atria. 4. Phosphoramidon (1 microM) and amastatin (10 microM) did not influence the potency of SS14 or SS28 in either the guinea-pig ileum or right atrium. In the guinea-pig vas deferens, phosphoramidon and amastatin did not affect the potency of SS28, but enhanced the potency of SS14 about 5 fold. Despite the presence of phosphoramidon and amastatin, SS28 was still more potent than SS14 in the vas deferens. 5. The putative somatostatin receptor blocking drug, cyclo(7-aminoheptanoyl Phe-D-Trp-Lys-Thr[Brl]) (CPP; 1 microM), did not antagonize the effects of either SS14 or SS28 in ileum, vas deferens or atrial preparations. 6. Somatostatin14 did not modify the contractile action of carbachol or alpha,beta-methylene ATP in the ileum and vas deferens respectively, suggesting that the site of the inhibitory effects on neurogenically mediated contractile responses in both preparations was pre-junctional. Consistent with this conclusion was the observation that the inhibitory effect of SS14 was markedly and inversely related to the external Ca2+concentration. The inhibitory effect of SS14 in guinea-pig atrium was only partly dependent on the external Ca2+ concentration.7. The somatostatin receptors mediating the inhibitory effect of SS14 in the ileum and vas deferens can be distinguished by the differential relative potencies of SS14 and SS28. In the former, SS14 and SS28 have similar potency whilst in the latter SS28 is much more potent. In this respect, the somatostatin receptor mediating negative inotropy in the guinea-pig right atrium appears similar to that identified in the vas deferens.8. We suggest that the somatostatin receptor mediating inhibition of neurogenic contraction in the ileum is similar to the recently cloned SSTR2 receptor. In contrast, the somatostatin receptor mediating negative inotropy in the atrium and inhibition of neurotransmission in the vas deferens appears similar to the SSTR4 receptor which recognises SS28 with higher affinity than SS14.
- 1 November 1993
- Published by Wiley in British Journal of Pharmacology
- Vol. 110 (3) , 1156-1164
Characterization of somatostatin receptors in guinea‐pig isolated ileum, vas deferens and right atrium
1. Somatostatin14 (SS14) inhibits neurogenically mediated contractile responses in guinea-pig ileum and vas deferens and exerts a direct negative inotropic action in guinea-pig spontaneously beating right atrium. In this study, the receptors mediating these inhibitory effects have been characterized by comparing the potencies of several cyclic somatostatin analogues. 2. In the guinea-pig ileum, SS14, somatostatin28 (SS28), somatostatin25 (SS25) and several smaller cyclic somatostatin analogues including octreotide, angiopeptin and CGP 23996, inhibited neurogenically mediated contractile responses, each being of similar potency. 3. In contrast, in the guinea-pig vas deferens and right atrium, SS28 was about 30 times more potent than SS14. However, although angiopeptin was nearly as potent as SS14 as an agonist in the vas deferens, in guinea-pig atrium angiopeptin had low intrinsic activity and antagonized the negative inotropic action of both SS14 and SS28 (pKB values of 7.4 and 7.2, respectively). CGP 23996 was 2-7 times weaker than SS14 in guinea-pig vas deferens and atria. 4. Phosphoramidon (1 microM) and amastatin (10 microM) did not influence the potency of SS14 or SS28 in either the guinea-pig ileum or right atrium. In the guinea-pig vas deferens, phosphoramidon and amastatin did not affect the potency of SS28, but enhanced the potency of SS14 about 5 fold. Despite the presence of phosphoramidon and amastatin, SS28 was still more potent than SS14 in the vas deferens. 5. The putative somatostatin receptor blocking drug, cyclo(7-aminoheptanoyl Phe-D-Trp-Lys-Thr[Brl]) (CPP; 1 microM), did not antagonize the effects of either SS14 or SS28 in ileum, vas deferens or atrial preparations. 6. Somatostatin14 did not modify the contractile action of carbachol or alpha,beta-methylene ATP in the ileum and vas deferens respectively, suggesting that the site of the inhibitory effects on neurogenically mediated contractile responses in both preparations was pre-junctional. Consistent with this conclusion was the observation that the inhibitory effect of SS14 was markedly and inversely related to the external Ca2+concentration. The inhibitory effect of SS14 in guinea-pig atrium was only partly dependent on the external Ca2+ concentration.7. The somatostatin receptors mediating the inhibitory effect of SS14 in the ileum and vas deferens can be distinguished by the differential relative potencies of SS14 and SS28. In the former, SS14 and SS28 have similar potency whilst in the latter SS28 is much more potent. In this respect, the somatostatin receptor mediating negative inotropy in the guinea-pig right atrium appears similar to that identified in the vas deferens.8. We suggest that the somatostatin receptor mediating inhibition of neurogenic contraction in the ileum is similar to the recently cloned SSTR2 receptor. In contrast, the somatostatin receptor mediating negative inotropy in the atrium and inhibition of neurotransmission in the vas deferens appears similar to the SSTR4 receptor which recognises SS28 with higher affinity than SS14.
- 8 March 1990
- Published by Oxford University Press (OUP)
- p. 147-172
5-HT in migraine: evidence from 5-HT1-like receptor agonists for a vascular aetiology
Regardless of the many considerations, GR43175 has been shown to be effective when administered subcutaneously and orally as well as when administered intravenously in the treatment of acute migraine. It is now in phase III clinical trials and promises to provide a major breakthrough in migraine therapy. Importantly, further studies on its clinical mechanism of action are in progress and they will, it is hoped, be invaluable in elucidating the pathogenesis of migraine and vascular headache.
- 8 March 1990
- Published by Oxford University Press (OUP)
- p. 147-172
5-HT in migraine: evidence from 5-HT1-like receptor agonists for a vascular aetiology
Regardless of the many considerations, GR43175 has been shown to be effective when administered subcutaneously and orally as well as when administered intravenously in the treatment of acute migraine. It is now in phase III clinical trials and promises to provide a major breakthrough in migraine therapy. Importantly, further studies on its clinical mechanism of action are in progress and they will, it is hoped, be invaluable in elucidating the pathogenesis of migraine and vascular headache.
- 1 January 1989
- Published by Emerald Publishing
- p. 35-9
GR43175 does not share the complex pharmacology of the ergots.
The aim of this study was to compare the effects of the selective 5-HT1-like receptor agonist, GR43175, with several ergot derivatives in several different pharmacological preparations. In the rat isolated uterus, ergotamine, dihydroergotamine, ergometrine and methylergometrine (all at concentrations of 1 microM) caused marked uterotonic activity whilst GR43175 (10 and 30 microM) was inactive. Similarly, in the pithed rat the ergot derivatives caused marked increases in diastolic blood pressure (in doses up to 1000 micrograms/kg intravenously), whilst GR43175 (in doses up to 1000 micrograms/kg intravenously) was inactive. In anaesthetized dogs, both ergotamine (0.3-1000 micrograms/kg intravenously) and GR43175 (1-1000 micrograms/kg intravenously) caused dose-dependent vasoconstriction in the carotid artery bed. However, the effects of ergotamine, unlike those of GR43175, were accompanied by increases in diastolic blood pressure and coronary vasoconstriction. These studies provide further evidence for the remarkably selective vasoconstrictor action of GR43175.
- 1 January 1989
- Published by Emerald Publishing
- p. 35-9
GR43175 does not share the complex pharmacology of the ergots.
The aim of this study was to compare the effects of the selective 5-HT1-like receptor agonist, GR43175, with several ergot derivatives in several different pharmacological preparations. In the rat isolated uterus, ergotamine, dihydroergotamine, ergometrine and methylergometrine (all at concentrations of 1 microM) caused marked uterotonic activity whilst GR43175 (10 and 30 microM) was inactive. Similarly, in the pithed rat the ergot derivatives caused marked increases in diastolic blood pressure (in doses up to 1000 micrograms/kg intravenously), whilst GR43175 (in doses up to 1000 micrograms/kg intravenously) was inactive. In anaesthetized dogs, both ergotamine (0.3-1000 micrograms/kg intravenously) and GR43175 (1-1000 micrograms/kg intravenously) caused dose-dependent vasoconstriction in the carotid artery bed. However, the effects of ergotamine, unlike those of GR43175, were accompanied by increases in diastolic blood pressure and coronary vasoconstriction. These studies provide further evidence for the remarkably selective vasoconstrictor action of GR43175.
- 1 January 1989
- Published by Portico in Drugs of the Future
- Vol. 14 (1)
SUMATRIPTAN SUCCINATE < Prop INNM; BAN >
- 1 January 1989
- Published by Portico in Drugs of the Future
- Vol. 14 (1)
SUMATRIPTAN SUCCINATE < Prop INNM; BAN >
- 1 February 1983
- Vol. 42 (2) , 218-22
Prejunctional effects of 5-hydroxytryptamine on noradrenergic nerves in the cardiovascular system.
Recent studies indicate that some peripheral noradrenergic nerves have specific 5-hydroxytryptamine (5-HT) receptors on their terminals that can mediate inhibition of release of transmitter after neuronal stimulation. It is now also known that 5-HT will cause norepinephrine release from noradrenergic nerve terminals in the isolated rabbit heart by a receptor mechanism. The evidence for the existence of these two types of prejunctional 5-HT receptor is discussed together with findings to date on their distribution and possible functional importance in the whole animal. In addition 5-HT has weak sympathomimetic actions, which result from its ability to interact with noradrenergic removal processes. The displaced transmitter can then interact with adrenoceptors situated pre- or postjunctionally.
- 1 February 1983
- Vol. 42 (2) , 218-22
Prejunctional effects of 5-hydroxytryptamine on noradrenergic nerves in the cardiovascular system.
Recent studies indicate that some peripheral noradrenergic nerves have specific 5-hydroxytryptamine (5-HT) receptors on their terminals that can mediate inhibition of release of transmitter after neuronal stimulation. It is now also known that 5-HT will cause norepinephrine release from noradrenergic nerve terminals in the isolated rabbit heart by a receptor mechanism. The evidence for the existence of these two types of prejunctional 5-HT receptor is discussed together with findings to date on their distribution and possible functional importance in the whole animal. In addition 5-HT has weak sympathomimetic actions, which result from its ability to interact with noradrenergic removal processes. The displaced transmitter can then interact with adrenoceptors situated pre- or postjunctionally.